EUVIMEDEUVIMED entdecken
Crossref

TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure

Maria Areli Lorenzana-Carrillo iD, Saymon Tejay iD, Joseph Nanoa iD, Guocheng Huang, Yongsheng Liu, Alois Haromy iD, Yuan Yuan Zhao, Michelle Mendiola Pla iD, Dawn E Bowles, Adam Kinnaird, Evangelos D Michelakis iD, Gopinath Sutendra iD

Circulation Research · 05.07.2024 · 135 (2) · 301-313

DOI: 10.1161/circresaha.123.324202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 05.07.2024. Verfasst von Maria Areli Lorenzana-Carrillo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (M.A.L.C., S.T., J.N., Y.L., A.H., Y.Y.Z., E.D.M., G.S.), University of Alberta, Edmonton, Canada. Hauptthemen laut MEDLINE: Heart Failure, Histones, Mice, Transgenic, Myocytes, Cardiac. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The tumor suppressor and proapoptotic transcription factor P53 is induced (and activated) in several forms of heart failure, including cardiotoxicity and dilated cardiomyopathy; however, the precise mechanism that coordinates its induction with accessibility to its transcriptional promoter sites remains unresolved, especially in the setting of mature terminally differentiated (nonreplicative) cardiomyocytes. METHODS: Male and female control or TRIM35 (tripartite motif containing 35) overexpression adolescent (aged 1–3 months) and adult (aged 4–6 months) transgenic mice were used for all in vivo experiments. Primary adolescent or adult mouse cardiomyocytes were isolated from control or TRIM35 overexpression transgenic mice for all in vitro experiments. Adenovirus or small-interfering RNA was used for all molecular experiments to overexpress or knockdown, respectively, target genes in primary mouse cardiomyocytes. Patient dilated cardiomyopathy or nonfailing left ventricle samples were used for translational and mechanistic insight. Chromatin immunoprecipitation and DNA sequencing or quantitative real-time polymerase chain reaction (qPCR) was used to assess P53 binding to its transcriptional promoter targets, and RNA sequencing was used to identify disease-specific signaling pathways. RESULTS: Here, we show that E3-ubiquitin ligase TRIM35 can directly monoubiquitinate lysine-120 (K120) on histone 2B in postnatal mature cardiomyocytes. This epigenetic modification was sufficient to promote chromatin remodeling, accessibility of P53 to its transcriptional promoter targets, and elongation of its transcribed mRNA. We found that increased P53 transcriptional activity (in cardiomyocyte-specific Trim35 overexpression transgenic mice) was sufficient to initiate heart failure and these molecular findings were recapitulated in nonischemic human LV dilated cardiomyopathy samples. CONCLUSIONS: These findings suggest that TRIM35 and the K120 Ub-histone 2B epigenetic modification are molecular features of cardiomyocytes that can collectively predict dilated cardiomyopathy pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHistonesMice, TransgenicMyocytes, CardiacTumor Suppressor Protein p53UbiquitinationAnimalsFemaleHumansMaleMiceCardiomyopathy, DilatedCells, CulturedMice, Inbred C57BLPromoter Regions, GeneticUbiquitin-Protein LigasesApoptosis Regulatory Proteins

Stichwörter der Autor:innen

apoptosisepigenomicsheart failurehistones

Substanzen

HistonesTumor Suppressor Protein p53Ubiquitin-Protein LigasesTrp53 protein, mouseTRIM35 protein, mouseApoptosis Regulatory Proteins

Autor:innen und Institutionen

  • Department of Medicine (M.A.L.C., S.T., J.N., Y.L., A.H., Y.Y.Z., E.D.M., G.S.), University of Alberta, Edmonton, Canada.
  • Cardiovascular Research Institute (M.A.L.C., S.T., J.N., Y.L., A.H., Y.Y.Z., E.D.M., G.S.), University of Alberta, Edmonton, Canada.
  • Cancer Research Institute of Northern Alberta (M.A.L.C., S.T., J.N., G.H., A.K., G.S.), University of Alberta, Edmonton, Canada.
  • Department of Surgery (G.H., A.K.), University of Alberta, Edmonton, Canada.
  • Department of Surgery, Duke University, Durham, NC (M.M.P., D.E.B.).

ORCID-Profile: Maria Areli Lorenzana-Carrillo, Saymon Tejay, Joseph Nanoa, Alois Haromy, Michelle Mendiola Pla, Evangelos D Michelakis, Gopinath Sutendra

Zitieren

APA

Lorenzana-Carrillo, M. A., Tejay, S., Nanoa, J., Huang, G., Liu, Y., Haromy, A., Zhao, Y. Y., Mendiola Pla, M., Bowles, D. E., Kinnaird, A., Michelakis, E. D., & Sutendra, G. (2024). TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure. Circulation Research, 135(2), 301-313. https://doi.org/10.1161/circresaha.123.324202

Vancouver

Lorenzana-Carrillo MA, Tejay S, Nanoa J, Huang G, Liu Y, Haromy A, et al. TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure. Circulation Research. 2024;135(2):301-313. doi:10.1161/circresaha.123.324202

BibTeX
@article{LorenzanaCarrillo2024,
  author = {Lorenzana-Carrillo, Maria Areli and Tejay, Saymon and Nanoa, Joseph and Huang, Guocheng and Liu, Yongsheng and Haromy, Alois and Zhao, Yuan Yuan and Mendiola Pla, Michelle and Bowles, Dawn E and Kinnaird, Adam and Michelakis, Evangelos D and Sutendra, Gopinath},
  title = {TRIM35 Monoubiquitinates H2B in Cardiac Cells, Implications for Heart Failure},
  journal = {Circulation Research},
  year = {2024},
  volume = {135},
  number = {2},
  pages = {301--313},
  doi = {10.1161/circresaha.123.324202}
}
Kostenlos starten →